No Data
Anhui Huaheng Biotechnology to Raise Capital of Two Subsidiaries to Boost Production
Express News | Huaheng Biotechnology: It plans to use the raised funds to increase the capital of its wholly-owned subsidiary to implement the investment and financing projects.
Huaheng Biology (688639): Amino acid price decline drags down performance, looking forward to new project production.
Event: Hua Heng Biology released the third quarter report of 2024, achieving revenue of 1.539 billion yuan, a year-on-year increase of 12.82%; net income attributable to shareholders of the listed company was 0.17 billion yuan, a year-on-year decrease of 46.90%. According to 2.
Huaheng Biology (688639): The price of valine is expected to stabilize. Pay attention to the situation of new product volume.
The company released the performance report for the first three quarters of 2024. In the first three quarters, the revenue reached 1.539 billion yuan, a year-on-year increase of 12.82%, achieving a net income attributable to the mother of 0.17 billion yuan, a year-on-year decrease of 46.9%. In the third quarter, the company
Huaheng Biology (688639): The company's third quarter profit in 2024 is awaiting improvement. Diversified product layout opens up growth space.
Event: On October 28, 2024, Huaheng Biology released the third quarter report of 2024, with a revenue of 1.539 billion yuan for the first three quarters of 2024, a year-on-year increase of 12.82%; net income attributable to shareholders was 1.70.
Huaheng Biology (688639): Short-term performance under pressure, focus on the pace of new product volume increase.
Investment highlights: Q3 performance under short-term pressure, successful implementation of private placement projects, successful commissioning of glycine project. Event: On October 28, 2024, the company released the third quarter report of 2024. Achieved in the first three quarters of 24 years ago
No Data
No Data